KANSARL Fusion Transcript Detection Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA-seq data analysis methods fail to accurately and efficiently map RNA-seq reads to genomes, resulting in suboptimal detection of fusion transcripts, which are crucial for cancer diagnosis and prognosis, as existing algorithms and software systems cannot balance speed and accuracy effectively.
Innovation Solution
A kit and method are developed for detecting KANSARL fusion transcripts using specific probes and primers that hybridize or amplify the unique junction sequences of these transcripts, allowing for their identification in biological samples, including various tissue types and cell lines, through hybridization-based methods like microarray analysis or PCR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing RNA-seq mapping algorithms and software systems are used, then fusion transcript detection can be performed, but both speed and accuracy are suboptimal as neither can achieve both fast speeds and high accuracies
Solution Approach 1:
The patent segments the RNA-seq read mapping process into distinct phases: initial rapid filtering of reads using k-mer based signatures, followed by focused alignment only for reads that pass the filter. This segmentation allows the system to achieve both high speed (through rapid filtering of the majority of reads) and high accuracy (through detailed alignment of candidate reads), resolving the contradiction between speed and accuracy in fusion transcript detection
Solution Approach 2:
The patent applies different quality levels of processing to different subsets of reads. High-speed, lower-compute processing is applied to all reads initially, while high-accuracy, high-compute processing is applied only to the small subset of reads that pass the filtering stage. This local quality approach ensures that computational resources are concentrated where they are most needed, achieving both speed and accuracy in the overall detection process
2Reliability
If comprehensive RNA-seq analysis is performed to identify novel fusion transcripts, then detection coverage is improved, but computational complexity and time requirements increase
Solution Approach 1:
The patent performs preliminary actions by pre-computing and storing k-mer based signatures for all reads before the actual fusion detection analysis. These pre-computed signatures enable rapid filtering in the main analysis phase without requiring complex real-time computations, thus improving detection coverage while managing computational complexity through advance preparation
Solution Approach 2:
The patent introduces k-mer based signatures as an intermediary representation between the raw RNA-seq reads and the final fusion transcript identification. This intermediary layer simplifies the comparison and matching processes, enabling comprehensive analysis of novel fusion transcripts while reducing the direct computational complexity of aligning and comparing full-length reads
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables the detection of novel fusion transcripts, improving the accuracy and speed of identifying KANSARL fusion transcripts, which are associated with cancer, particularly in samples of European ancestry, thereby enhancing cancer diagnosis and prognosis.
Implementation Method 1
at least one probe, wherein each of the at least one probe comprises a sequence that hybridizes specifically to a junction of the at least one KANSARL fusion transcript
Implementation Method 2
at least one pair of amplification primers, wherein each of the at least one pair of amplification primers are configured to specifically amplify the at least one KANSARL fusion transcript
Data Source
Figure 1A~1B
Figure 1C~1E
Figure 2A~2F
AI summary
This present disclosure provides a kit and method for detecting at least one KANSARL fusion transcript from a biological sample from a subject. The kit comprises at least one of the following components: (a) at least one probe, wherein each of the at least one probe comprises a sequence that hybridizes specifically to a junction of the at least one KANSARL fusion transcript; (b) at least one pair of probes, wherein each of the at least one pair of probes comprises: a first probe comprising a sequence that hybridizes specifically to KANSL1; and a second probe comprising a sequence that hybridizes specifically to ARL17A; or (c) at least one pair of amplification primers, wherein each of the at least one pair of amplification primers are configured to specifically amplify the at least one KANSARL fusion transcript.